Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib in Combination With ASTX727 in Relapsed/Refractory TP53 Mutated AML
NCT05396859Phase 1Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entrectinib in acute myeloid leukemia (AML), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of dose limiting toxicities at 28 days. Started Oct 2022; status: active, not recruiting.
02
Drugs
entrectinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05396859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396859.